Pharmaceuticals · NYSE
MRKMerck & Co., Inc.
- Last close
- $147.76 +0.6%
- 52-week range
- $91.49 to $156.92
- Market cap
- $364B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Above its 10-year median on all 4 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 152x
- Earnings yield
- 0.7%
- Price / sales
- 5.4x
- Price / book
- 8.1x
- Price / operating cash flow
- 19.5x
- EV / EBITDA
- 40.3x
- EV / sales
- 6.1x
- Free cash flow yield
- 4.0%
Profitability
- Gross margin
- 71.8%
- Operating margin
- n/a
- Net margin
- 3.6%
- Return on equity
- 5.5%
- Return on capital
- n/a
n/a: Not reported
Growth per year
- Revenue, 3 years
- +3.1%
- Revenue, 5 years
- +9.4%
- Revenue, 9 years
- +5.6%
- EPS, 3 years
- +8.4%
Balance sheet
- Cash and investments
- $9.65B
- Total debt
- $53.8B
- Net cash
- -$44.1B
- Debt / equity
- 1.20x
- Current ratio
- 1.35x
Shares and dividend
- Shares outstanding
- 2.47B
- Share count, 5 years
- -1.3%
- Beta, 1 year
- 0.19
- Dividend yield
- 2.3%
- Dividend per share, TTM
- $3.40
- Payout ratio
- 341%
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
US went from 46% to 56% of revenue in 3 years
Share of revenue by region, fiscal 2022 to 2025, as reported in the 10-K.
| Region | Revenue | Share | vs FY24 |
|---|---|---|---|
| US | $36.5B | 56.2% | +13% |
| EMEA | $14.6B | 22.4% | +4% |
| Latin America | $3.41B | 5.2% | -1% |
| Asia Pacific | $2.98B | 4.6% | -2% |
| Other Countries | $2.88B | 4.4% | +12% |
| JP | $2.71B | 4.2% | -17% |
| CN | $1.94B | 3.0% | -65% |
Pharmaceuticals peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| LLY ELI LILLY & Co | $1.36T | +46% | n/a | 46.8x | 15.7x | 60th percentile |
| JNJ Johnson & Johnson | $688B | +8% | n/a | 43.4x | 6.9x | 90th percentile |
| MRK Merck & Co., Inc. | $364B | +5% | n/a | 152x | 5.4x | 98th percentile |
| PFE Pfizer Inc | $165B | +1% | n/a | 41.2x | 2.6x | 97th percentile |
| BMY Bristol Myers Squibb Co | $130B | +4% | n/a | 14.1x | 2.6x | 13th percentile |
| TEVA Teva Pharmaceutical Industries Ltd | $51.9B | -16% | 10.2% | 103x | 3.7x | Not enough history |
The company
- Sector
- Health Care
- Industry
- Pharmaceuticals
- CEO
- Kenneth Frazier
- Employees
- 70,000 (as of 2015)
- Founded
- 1891
- Headquarters
- Rahway, NJ
- Fiscal year ends
- December
- Website
- msd.no
What it does
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about MRK.
Held by 3,522 active funds. Crowd level: crowd building, 3 rising quarters.
Open the Smart money tab